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Background: The mechanisms of chronic cough are unclear. Many reactive oxygen species affect airway sensory
C-fibres which are capable to induce cough. Several chronic lung diseases are characterised by cough and oxidative
stress. In asthma, an association between the cough severity and airway oxidative stress has been demonstrated.
The present study was conducted to investigate whether airway oxidative stress is associated with chronic cough in
subjects without chronic lung diseases.
Methods: Exhaled breath condensate samples were obtained in 43 non-smoking patients with chronic cough and
15 healthy subjects. Exclusion criteria included a doctor’s diagnosis of any lung disorders and any abnormality in
lung x-ray. The concentration of 8-isoprostane was measured. In addition, the patients filled in Leicester Cough
Questionnaire and underwent hypertonic saline cough provocation test, spirometry, ambulatory peak flow monitoring,
nitric oxide measurement, and histamine airway challenge. In a subgroup of patients the measurements were repeated
during 12 weeks’ treatment with inhaled budesonide, 800 ug/day.
Results: The 8-isoprostane concentrations were higher in the cough patients than in the healthy subjects (24.6 ±
1.2 pg/ml vs. 10.1 ± 1.7 pg/ml, p = 0.045). The 8-isoprostane concentration was associated with the Leicester Cough
Questionnaire total score (p = 0.044) but not with the cough sensitivity to saline or other tests. Budesonide treatment
did not affect the 8-isoprostane concentrations.
Conclusions: Chronic cough seems to be associated with airway oxidative stress in subjects with chronic cough but
without chronic lung diseases. This finding may help to develop novel antitussive drugs.
Trial registration: The study was registered in ClinicalTrials.gov database (KUH5801112), identifier NCT00859274.
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Chronic cough is reported by 10 – 20% of general popu-
lation [1]. It is the most common condition for which
patients seek consultation from a doctor [2]. The mech-
anisms of chronic cough are poorly understood. As a
consequence, there are very few therapeutic options for
patients with unexplained chronic cough. There is a
pressing need to understand the genetic, molecular, and
physiological basis of chronic cough and to develop
novel antitussive drugs [3].
During the recent years the concept of chronic cough as
a sensory neuropathy has been widely accepted [4]. C-
fibres represent one of the two main sensory pathways to
initiate cough reflex and are often thought to be the prin-
cipal fibres mediating cough in pathological conditions [5].* Correspondence: heikki.koskela@kuh.fi
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article, unless otherwise stated.Many reactive oxygen (ROS) and nitrogen (RNS) species
activate sensory bronchopulmonary C- fibres, probably
through Transient Receptor Potential A1 channels [6-8].
Peroxidation of arachidonic acid by ROS leads to for-
mation of isoprostanes [9]. Animal studies show that iso-
prostanes sensitise C-fibres in a concentration-dependent
manner [10].
An imbalance between the manifestation of ROS and
an organ’s ability to detoxify them is called the oxidative
stress. Many chronic lung diseases including asthma,
chronic obstructive pulmonary disease, cystic fibrosis,
and fibrosing lung diseases are characterised by oxida-
tive stress [11-17]. Cough is a typical symptom of all
these disorders. In asthma, high exhaled breath conden-
sate (EBC) 8-isoprostane levels are associated with poor
cough-associated quality of life and hypersensitivity to
the cough-provoking effect of hyperpnoea [18]. Thus, air-
way oxidative stress may be involved in the pathogenesisCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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function of sensory bronchopulmonary C- fibres. However,
in the majority of patients with chronic cough there is no
evidence of chronic lung diseases. The present study was
planned to investigate whether airway oxidative stress is
present also in subjects without doctor’s diagnosis of any
chronic lung disorders but who seek medical advice due to
chronic cough.Methods
Subjects
Forty-three subjects with chronic cough of at least eight
weeks’ duration were recruited using newspaper adver-
tisements. Exclusion criteria were a doctor’s diagnosis of
asthma at present or previously, doctor’s diagnosis of any
other lung disorder, current smoking, any abnormalities in
chest x-ray, and a febrile respiratory tract infection within
six weeks. In addition, 15 healthy, non-smoking subjects
were recruited from the personnel of the authors’ depart-
ment. Table 1 shows the characteristics of the subjects.
The study was performed in accordance with the Good
Clinical Practice guidelines recommended by the Dec-
laration of Helsinki. The study was approved by the ins-
titutional Ethics Committee (132//2008) as well as the
National Agency for Medicines (EudraCT 2009-009556-
21). The study was registered in ClinicalTrials.gov da-
tabase (KUH5801112), identifier NCT00859274. Written
informed consent was obtained from each subject prior to
participation in the study.Table 1 The basic characteristics of the subjects
Characteristic Subje
Age (years) 55.6 ±
Females – number (%) 32 (74
Ex smokers – number (%) 20 (47
Atopic patients – number (%) 14 (33
Duration of cough (years) 8.5 ± 1
Most probable cause of cougha, Rhiniti
- number (%) Esoph
Asthm
Leicester questionnaire total score 13.2 ±
Cough sensitivity to hypertonic saline (coughs/Osmol/kg) 7.24 ±
Histamine PD15 (mg)
b 1.28 ±
Nitric oxide concentration (ppm) 16.8 ±
FEV1 (% of predicted) 93.7 ±
PEF variation in ambulatory monitoring (%) 7.13 ±
Continuous data is expressed as means and standard errors. ND = not done; FEV1:=
to induce a 15% fall in FEV1. PEF = peak expiratory flow.
aBased on the results of the Cough Clinic diagnostic questionnaire. Two patients ha
bAmong subjects without a 15% fall in FEV1 in response to histamine, an arbitrary v
patient due to technical reasons.Study design
This was a prospective study including a wide range of
baseline measurements and an open-label treatment phase
in a subgroup of cough patients (Figure 1). Its methods
and clinical results have been published previously [19].
The present paper describes the results of the EBC ana-
lysis of 8-isoprostane.
At baseline, the patients with chronic cough underwent
the following tests and measurements: The Leicester
Cough Questionnaire (LCQ) [20] and The Cough Clinic
diagnostic questionnaire [21] were filled in. A chest x-ray,
skin prick tests, exhaled air nitric oxide (NO) measure-
ment, ambulatory peak expiratory flow (PEF) monitoring,
histamine airway challenge [22], spirometry, and hyper-
tonic saline cough provocation test [23] were performed.
Histamine challenge and the saline test were performed
on separate days. In the cough patients, the first EBC was
collected after the spirometry, before the saline test, and
the second two minutes after the saline test. The healthy
subjects did not perform the spirometry and the saline test
but only underwent the EBC sample collection.
The treatment phase was participated by the cough
patients who were responsive to the hypertonic saline
test (N = 21). For the next twelve weeks, they used
budesonide inhalation powder 400 ug twice a day
(Budesonid Easyhaler, Orion Ltd, Espoo, Finland). The
EBC samples were collected and the Leicester Cough
Questionnaire was filled in at one, four, and twelve
weeks. In one subject the baseline EBC sample was
missed due to technical reasons, two subjects did notcts with chronic cough (N = 43) Healthy subjects (N = 15)





s 22 (51) ND








forced expiratory volume in one second; PD15 = provocative dose of histamine
d more than one most probable cause.
alue of 3.2 mg was used as PD15. Histamine challenge was missed in one
Baseline measurements: 43 
patients with chronic cough
12-weeks treatment phase: 
21 cough patients
1 patient with missed samples
1 patient with poor drug 
compliance
2 patients discontinued 
17 patients completed the 
treatment phase with 
satisfactory drug compliance
15 healthy subjects
Figure 1 The subject flow chart.
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have non-satisfactory drug compliance.
Leicester Cough Questionnaire
The Leicester Cough Questionnaire is a 19-item validated,
repeatable and responsive questionnaire consisting of phys-
ical, psychological and social domains. Answers are graded
on 7-point Likert scale which gives a total score ranging
from 3 to 21. A small score indicates poor cough-related
quality of life [20].
The Cough Clinic diagnostic questionnaire
The Cough Clinic diagnostic questionnaire includes 16
questions designed to differentiate the three common
causes of chronic cough (gastro-oesophageal reflux dis-
ease, asthma, and rhinitis). The three components of the
questionnaire are validated but the whole questionnaire
and algorithm is not [21]. Idiopathic chronic cough can-
not be detected by this questionnaire.
Hypertonic saline cough provocation test
First, spirometry was performed for three times. The sub-
jects inhaled 0.4 mg of salbutamol to prevent bronchocon-
striction. Fifteen minutes after the salbutamol inhalation
the spirometry was repeated. Then the subject inhaled
isotonic phosphate-buffered saline for two minutes via a
high-output ultrasonic nebuliser (DeVilbiss Ultraneb 3000,
Sunrise Medical Ltd, West Midlands, UK), using tidal
breathing. The coughs occurring during the inhalationand two minutes after it were counted up. The number of
these “spontaneous” coughs was subtracted from the
coughs provoked by each hypertonic solution. Subse-
quently, they inhaled hypertonic phosphate-buffered saline
solutions with osmolalities of 600, 900, 1200, 1500, 1800
and 2100 mOsm/kg. The challenge was stopped if the
subject asked for it or if 15 or more cumulative coughs
were recorded. Two minutes after the final saline solution
the spirometry was repeated [23].
The cough sensitivity to hypertonic saline was expressed
as the cumulative number of provoked coughs divided by
the final osmolality inhaled (CDRsaline). The unit of this
index is coughs/Osmol/kg.
Collection and analysis of the EBC
EBC was collected according to published guidelines
[24] utilizing a commercially-available device (Ecoscreen
Turbo, VIASYS Healthcare GmbH, Höchberg, Germany).
The device has a salivary trap to avoid salivary contamin-
ation of the samples. The subjects sat and wore a nose
clip. The duration of collection was 10 minutes, using tidal
breathing. The condensate was stored in – 70°C and ana-
lysed afterwards. The 8-isoprostane concentrations were
measured by enzyme immunoassay utilizing a commercial
reagent according to the manufacturer’s instructions
(Cayman Chemical Company, Ann Arbor, MI, USA).
Samples were diluted directly in EIA Buffer without purifi-
cation. A standard curve was established by dilution of the
8-isoprostane EIA Standard between 1500 pg/ml and
2.5 pg/ml, using EIA Buffer as the matrix.
Altogether, 217 EBC samples were obtained during the
study. In 38 samples (18%) the 8-isoprostane concentra-
tions were below the detection limit of the assay. In
these samples, an arbitrary value of 1.25 pg/ml was uti-
lized for statistical purposes. Baseline EBC sample was
missed in one subject due to technical reasons.
Statistical analysis
The continuous data is expressed as means and standard
errors. The distributions of the EBC 8-isoprostane con-
centrations and histamine airway responsiveness differed
significantly from the normal distribution (p < 0.05,
Kolmogorov-Smirnov test). However, these values were
normally distributed after logarithmic transformation.
Therefore, log-transformed values were used for para-
metric statistics and geometric means and standard er-
rors were expressed. T-tests, repeated measures analysis
of variance, Pearson correlation coefficient (Rp), and
analysis of covariance with backwards directed stepwise
procedure were utilized when appropriate.
Results
The baseline, pre-saline EBC 8-isoprostane concentrations
were higher in the cough patients than in the healthy
Figure 3 Association of the exhaled breath condensate (EBC)
8-isoprostane concentration and Leicester Cough Questionnaire
(LCQ) total score among 43 patients with chronic cough
(Rp = −0.29, p = 0.06). Low LCQ total score indicates poor cough-
related quality of life.
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Figure 2). According to the Cough Clinic diagnostic ques-
tionnaire, the most probable underlying condition among
the cough patients were rhinitis (22 patients) esophageal
reflux (14 patients), and asthma (9 patients). In two pa-
tients the questionnaire suggested more than one under-
lying condition. Exclusion of the nine possible asthmatic
patients from analysis did not affect these results signifi-
cantly: The corresponding 8-isoprostane concentrations
were 24.0 ± 1.2 pg/ml in the cough patients and 10.1 ±
1.7 pg/ml in the healthy subjects ( p = 0.063).
Within the cough patients, a suggestive association be-
tween the baseline EBC 8-isoprostane concentration and
the LCQ total score was found in the bivariate analysis
(Rp = −0.29, p = 0.06, Figure 3). This association was much
closer in men than in women (Rp = −0.77, p = 0.006 vs.
Rp = −0.11, p = 0.54, respectively, Figure 4). When sex was
included in the multivariate analysis, the association
between baseline EBC 8-isoprostane concentration and
the LCQ total score was statistically significant within the
whole group of cough patients (p = 0.044).
The baseline EBC 8-isoprostane concentration did not
correlate statistically significantly with PEF variation in
ambulatory monitoring, spirometric indices, NO level,
histamine airway responsiveness, and hypertonic saline
cough responsiveness. The mean 8-Isoprostane concentra-
tions did not differ between men and women (22.2 ± 1.4
vs. 25.6 ± 1.3 pg/ml, respectively (p = 0.75)). Furthermore,
there were no differences in EBC 8-isoprostane concentra-
tions between the patient groups divided according to the
most probable underlying cause of chronic cough.
The 12-week budesonide treatment did not affect the
EBC 8-isoprostane concentrations significantly (p =
0.39). There was no association between the baseline
EBC 8-isoprostane and the maximal improvement inFigure 2 Comparison of the exhaled breath condensate (EBC)
8-isoprostane concentrations between 15 healthy subjects and
43 patients with chronic cough.LCQ total score during the budesonide treatment (Rp =
0.06, p = 0.70).
The saline test did not affect the EBC 8-isoprostane
concentrations: There were 100 pairs of EBC samples
collected before and after the saline test. The 8-
isoprostane concentrations were 17.9 ± 1.1 pg/ml and
16.6 ± 1.2 pg/ml (p = 0.56). The intraclass correlation co-
efficient between the pre- and post-saline measurements
was 0.72.
Discussion
The present study shows that airway oxidative stress
may be associated with chronic cough among non-
smoking patients without a doctor’s diagnosis of anyFigure 4 Association of the exhaled breath condensate (EBC)
8-isoprostane concentration and Leicester Cough Questionnaire
(LCQ) total score among the 11 male patients with chronic
cough (Rp = −0.77, p = 0.006). Low LCQ total score indicates poor
cough-related quality of life.
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First, the concentrations of EBC 8-isoprostane were
higher in the patients with chronic cough than in the
healthy subjects. Second, the EBC 8-isoprostane concen-
trations were associated with the Leicester Cough Ques-
tionnaire total scores within the cough patients.
The study population was recruited utilising a news-
paper advertisement and probably well represents typical
patients seeking help for chronic cough of unknown ori-
gin. The three most common underlying disorders among
such patients are gastro-oesophageal reflux disease,
asthma, and rhinitis [25]. Though a doctor’s diagnosis of
any chronic lung disease was used as an exclusion criter-
ion, nine of the present patients may have suffered from
asthma, according to the Cough Clinic diagnostic ques-
tionnaire. It is well known that asthma is characterised by
oxidative stress [13]. However, exclusion of the probable
asthma patients from analysis did not affect the results sig-
nificantly. Furthermore, there were no differences in EBC
8-isoprostane concentrations between the patient groups
divided according to the most probable underlying cause
of chronic cough. We acknowledge that the study group
was too small for a subgroup analysis. However, these
findings suggest that cough itself is the phenomenon asso-
ciated with oxidative stress, not the underlying disorder.
This is in close accordance with the new concept of cough
as a sensory neuropathy [4].
Measurement of F(2)-isoprostanes is considered as the
most reliable approach to assess oxidative stress status
in vivo [26]. F(2) isoprostanes are stable compounds and
relatively abundant in all normal biologic fluids and tis-
sues. The most prevalent isoprostane in humans is 8-epi-
PGF2α, also known as 8-isoprostane [27,28]. The presently
utilized EIA kit to analyse 8-isoprostane is widely used in
EBC samples [18,29-40], is validated against mass spec-
trometry [38], and has acceptable repeatability [38,41].
The short-term repeatability was satisfactory also in the
present study when comparing the pre- and post-saline
measurements. However, the present study suffers from
similar difficulties to all studies utilising EBC samples.
EBC is a very dilute solution of biomarkers and for many
of them, assays are often employed at or near their detec-
tion limits [24]. This was also the case in the present study
with 18% of the samples being below the detection limit of
the 8-isoprostane assay. Therefore, the results should be
interpreted cautiously.
As mentioned in the introduction, there is solid experi-
mental evidence suggesting that airway oxidative stress
might be involved in chronic cough with many ROS and
RNS and their metabolites being capable to affect the
function of sensory bronchopulmonary C-fibres [6-8,10].
The sources of ROS and RNS in the airways can be both
endogenous and exogenous [42]. The exogenous sources
of ROS and RNS are various environmental pollutants,especially airborne particulate matter and cigarette
smoke [43-46]. The main endogenous ROS and RNS in
the lung come from inflammatory cells like neutrophils,
eosinophils, and alveolar macrophages, but also from
structural cells [47]. This may explain the presence of
oxidative stress in many chronic inflammatory lung
diseases [13,15-17].
Various inflammatory cells have also been found in the
airways of patients with chronic cough [48-50]. A lympho-
cytic airway inflammation has been identified in some pa-
tients with idiopathic chronic cough and organ specific
autoimmune diseases [51]. In chronic cough, inflamma-
tion may be a consequence of mechanical trauma of
coughing [52]. This might explain the facts that oxidative
stress could be demonstrated in this kind of unselected
cough population and that there were no differences in
EBC 8-isoprostane concentrations between the subgroups
with different possible causes of cough.
If inflammation is a consequence of coughing, oxida-
tive stress might be the key factor to initiate a vicious
circle of chronic cough: The original trigger may pro-
voke cough that causes traumatic inflammation in the
airways [52]. The inflammatory cells, in turn, generate
ROS and RNS [47] which act on sensory C-fibres and
thus induce further cough and secondary traumatic in-
flammation. By this means cough could continue even
though the original trigger for cough may have disap-
peared long ago.
The association between 8-isoprostane and Leicester
Cough Questionnaire total score was much closer in
men than in women. This is difficult to explain. The
mean 8-Isoprostane concentrations did not differ be-
tween the sexes. Epidemiological studies usually report
similar prevalence of chronic cough in men and women
[53]. However, data of specialist cough clinics clearly
show that women more often than men seek medical ad-
vice due to cough [54]. Women were also overrepre-
sented in the present study which recruited the subjects
utilising newspaper advertisements. This may indicate
that there are differences how men and women experi-
ence cough and might partly explain the finding of the
present study.
In the present study population cough responsiveness
to hypertonic saline did not correlate with the EBC 8-
isoprostane concentration. On the contrary, a statisti-
cally significant correlation between the two biomarkers
has been demonstrated among asthmatic patients. Fur-
thermore, no association could be seen between cough
responsiveness to hypertonic saline and LCQ total score
in the present study. Again, a very close association be-
tween the two has been demonstrated in asthmatic pa-
tients [55]. These findings suggest that hypertonic saline
cough provocation test reflects the cough severity better
in asthma than in non-specific chronic cough.
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bulatory PEF variation, spirometric indices, NO level, and
airway histamine responsiveness correlated statistically sig-
nificantly with EBC 8-isoprostane. This suggests that the
pathogenesis of airway oxidative stress in chronic cough is
different from asthma pathogenesis.
The present study as well as previous studies
[31,41,56,57] consistently show that the effect of inhaled
corticosteroids on EBC 8-isoprostane concentrations is
negligible. The previous follow-up studies about this
issue may be criticized on the basis of short duration of
corticosteroid treatment (3 – 4 weeks) but the present
study shows that even a 12 weeks’ treatment with in-
haled corticosteroid does not affect EBC 8-isoprostane
concentrations in a statistically significant manner.
Given that EBC 8-isoprostane analysis is considered as
a reliable approach to assess airway oxidative stress sta-
tus [27,28] it seems that inhaled corticosteroids have
minor effect on airway oxidative stress. This finding
may explain the poor effect of inhaled corticosteroids in
many patients with chronic cough. The beneficial effect
of corticosteroids in certain patients with chronic cough
[19,58,59] is probably mediated through suppression of
airway eosinophilic inflammation [49,60].
This study may be criticised by the fact that EBC was
collected after the spirometry in the cough patients
whereas in the healthy subjects spirometry was not per-
formed. To the best of the authors’ knowledge, there are
no studies about the effect of forced expiratory manoeu-
vres on EBC 8-isoprostane concentration. If such an effect
does exist, it may have affected the described difference in
EBC 8-isoprostane concentration between the cough
patients and the healthy subjects.Conclusions
The results of the present study, together with the earl-
ier one among asthmatic patients [18], suggest that
airway oxidative stress may be involved in the pathogen-
esis of chronic cough. Airway oxidative stress may be
the common factor behind cough in various pulmonary
and extrapulmonary disorders and could, at least partly,
clarify the mechanisms of sensory neuropathy in chronic
cough [4]. Further studies aiming at assessing oxidative
stress in subjects with chronic cough using independ-
ent non-invasive techniques, including e-noses [61,62]
and nuclear magnetic resonance spectroscopy of EBC
[63,64], should be undertaken. The inability of inhaled
corticosteroids to suppress airway oxidative stress may
explain the often unsatisfactory effect of these drugs on
chronic cough. The present findings may help to develop
novel antitussive drugs. Inhaled antioxidants might be an
interesting treatment option to be evaluated in chronic
cough.Abbreviations
CDR: Coughs-to-dose ratio; EBC: Exhaled air condensate; LCQ: Leicester
Cough Questionnaire; NO: Exhaled air nitric oxide concentration; PEF: Peak
expiratory flow; RNS: Reactive nitrogen species; ROS: Reactive oxygen species;
Rp: Pearson correlation coefficient.
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